We are live on ! Find out more
Abingworth

Abingworth Portfolio holdings

AUM $304M Turnover 0%
1-Year Est. Return 95.02%
This Fund
S&P 500
This Quarter Est. Return
-23.1%
1 Year Est. Return
+95.02%
3 Year Est. Return
+186.67%
5 Year Est. Return
+346.26%
10 Year Est. Return
–
AUM
$171M
AUM Growth
-$49.1M
Cap. Flow
+$32.3M
Cap. Flow %
18.88%
Top 10 Hldgs %
94.62%
Holding
20
New
4
Increased
–
Reduced
1
Closed
3
Avg Time Held
0.9 years
Top 10 Avg Time Held
0.8 years
Top 20 Avg Time Held
0.9 years

Top Sells

Rank Stock Value
1
AMRN icon
Amarin
AMRN
+$19.8M
2
ZGNX
Zogenix
ZGNX
+$3.92M
3
CEMP
Cempra
CEMP
+$1.67M
4
ZLCS
Zalicus
ZLCS
+$45K

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Miscellaneous 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
CHMA
1
DELISTED
Chiasma
CHMA
$41.4M 24.16%
+2,080,595
New +$51.7M
2015 Q3
0 quarters
TARA icon
2
Protara Therapeutics
TARA
$148M
$27.4M 16.02%
50,447
– –
2014 Q4
3 quarters
PRTK
3
DELISTED
Paratek Pharmaceuticals
PRTK
$24.7M 14.43%
1,301,413
– –
2014 Q4
3 quarters
SIEN
4
DELISTED
Sientra
SIEN
$22.3M 13.04%
219,901
– –
2014 Q4
3 quarters
EVAR
5
DELISTED
Lombard Medical
EVAR
$12.3M 7.2%
3,473,452
– –
2014 Q3
4 quarters
CEMP
6
DELISTED
Cempra
CEMP
$10.7M 6.24%
383,935
-45,000
-10% -$1.67M
2013 Q2
9 quarters
DRNA
7
DELISTED
Dicerna Pharmaceuticals
DRNA
$7.76M 4.53%
945,757
– –
2014 Q1
6 quarters
INNL
8
DELISTED
Innocoll Holdings
INNL
$6.69M 3.91%
555,555
– –
2015 Q2
1 quarter
TBRA
9
DELISTED
Tobira Therapeutics
TBRA
$5.66M 3.3%
589,244
– –
2015 Q2
1 quarter
CBAY icon
10
DELISTED
Cymabay Therapeutics
CBAY
$3.07M 1.79%
+1,600,000
New +$4.36M
2015 Q3
0 quarters
ANTH
11
DELISTED
Anthera Pharmaceuticals
ANTH
$2.67M 1.56%
54,749
– –
2013 Q2
9 quarters
RGLS icon
12
DELISTED
Regulus Therapeutics
RGLS
$2.14M 1.25%
2,728
– –
2014 Q1
6 quarters
DERM icon
13
DELISTED
Dermira
DERM
$1.62M 0.95%
+70,000
New +$1.7M
2015 Q3
0 quarters
QUIT icon
14
Achieve Life Sciences
QUIT
$646M
$1.33M 0.78%
274
– –
2013 Q2
9 quarters
CCXI icon
15
DELISTED
ChemoCentryx
CCXI
$1.3M 0.76%
215,000
– –
2015 Q1
2 quarters
DCOY icon
16
Decoy Therapeutics
DCOY
$2.08M
– –
0
– –
2015 Q1
2 quarters
EPRS
17
DELISTED
Epirus Biopharmaceuticals
EPRS
$35K 0.02%
+7,896
New +$46.4K
2015 Q3
0 quarters
AMRN icon
18
Amarin
AMRN
$473M
– –
-404,374
Closed -$19.8M –
ZGNX
19
DELISTED
Zogenix
ZGNX
– –
-291,902
Closed -$3.92M –
ZLCS
20
DELISTED
Zalicus
ZLCS
– –
-7,896
Closed -$45K –

Similar funds

Abingworth's Q3 2015 Portfolio in Review

As of Q3 2015, Abingworth held 20 positions worth $171M, down 22% from $220M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Abingworth deployed $32.3M of net new capital in Q3 2015, opening 4 new positions. Its largest new stake was Chiasma: 2,080,595 shares worth $41.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Cempra, an estimated $1.67M trimmed.

  • Abingworth's largest Q3 2015 buy was Chiasma: 2,080,595 shares worth $41.4M.
  • Abingworth's biggest Q3 2015 reduction was Cempra, cutting an estimated $1.67M.
  • Abingworth fully exited Amarin in Q3 2015, selling an estimated $19.8M.
  • Abingworth's ten largest holdings make up 95% of its $171M portfolio in Q3 2015.
  • Abingworth opened 4 new positions and closed 3 in Q3 2015.
  • Abingworth's portfolio value fell 22% quarter-over-quarter to $171M.

Based on Abingworth's 13F filing for Q3 2015, filed 13 Nov 2015.